3-2020

Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease

Florin Despa
*University of Kentucky*, f.despa@uky.edu

Larry B. Goldstein
*University of Kentucky*, larry.goldstein@uky.edu

Geert Jan Biessels
*University Medical Center Utrecht, the Netherlands*

Follow this and additional works at: [https://uknowledge.uky.edu/pharmacol_facpub](https://uknowledge.uky.edu/pharmacol_facpub)

Part of the Neurology Commons, and the Pharmacology, Toxicology and Environmental Health Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation
Despa, Florin; Goldstein, Larry B.; and Biessels, Geert Jan, "Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease" (2020). *Pharmacology and Nutritional Sciences Faculty Publications*. 104.
[https://uknowledge.uky.edu/pharmacol_facpub/104](https://uknowledge.uky.edu/pharmacol_facpub/104)

This Letter to the Editor is brought to you for free and open access by the Pharmacology and Nutritional Sciences at UKnowledge. It has been accepted for inclusion in Pharmacology and Nutritional Sciences Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease

Digital Object Identifier (DOI)
https://doi.org/10.1002/ana.25668

Notes/Citation Information
Published in *Annals of Neurology*, v. 87, issue 3.

© 2020 American Neurological Association

This is the pre-peer-reviewed version of the following article: Despa, F., Goldstein, L. B., & Biessels, G. J. (2020). Amylin as a potential link between type 2 diabetes and Alzheimer disease. *Annals of Neurology, 87*(3), 486-486, which has been published in final form at https://doi.org/10.1002/ana.25668. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

This letter to the editor is available at UKnowledge: https://uknowledge.uky.edu/pharmacol_facpub/104
Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease

Florin Despa, PhD¹,², Larry B. Goldstein, MD², Geert Jan Biessels, MD, PhD³

¹Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA ²Department of Neurology, University of Kentucky, Lexington, KY, USA ³Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands

Martinez-Valbuena et al.¹ provide histological evidence of amylin-β amyloid (Aβ) and amylin-tau cross-seeding in both pancreatic and brain tissues, suggesting a possible connection in the pathogenesis of Alzheimer’s disease (AD) and type 2 diabetes. They noted pancreatic amylin-Aβ and amylin-tau deposits in humans with AD in the absence of type-2 diabetes, which the authors interpreted as potential evidence for a role of Aβ and tau tangle pathology in insulin resistance in these subjects. We suggest an alternative interpretation of this finding that we base on four key observations: 1, pancreatic β-cells express and process both the Aβ protein precursor and tau mRNAs² implying that amylin-Aβ and amylin-tau inclusions may originate from the pancreas; 2, affected age-groups and clinical trajectories in type-2 diabetes and late-onset AD generally indicate that diabetes most commonly precedes AD and is associated with an acceleration of the transition from mild cognitive impairment to dementia; 3, consistent with this observation and because rodent amylin is non-amyloidogenic, rodent AD models do not develop type-2 diabetes, whereas pancreatic expression of amyloid-forming human amylin in non-AD rats causes type-2 diabetes, brain amylin deposition and behavior deficits³; and 4, the brain region involved in the central regulation of pancreatic β-cell function (i.e., the hypothalamus)⁴ is affected by AD pathology. Consequently, AD may impair central signaling pathways that regulate amylin secretion leading to pancreatic β-cell dysfunction and impaired clearance of amylin, Aβ and tau. We therefore posit that the presence of mixed amylin-Aβ or amylin-tau inclusions in the pancreatic β-cells of patients with AD may reflect an in situ stress response to comorbid endocrine dysfunction and amylin dyshomeostasis.

Martinez-Valbuena et al¹ highlight the complex mechanisms underlying pancreatic β-cell dysfunction and linked amylin-Aβ and amylin-tau pathology in type-2 diabetes. Taken together with published evidence showing the presence of mixed amylin-Aβ pathology in human AD², these new data¹ provide support for the hypothesis that overexpression and/or impaired clearance of amyloidogenic proteins (amylin, Aβ, tau) are critical pathological pathways in both type-2 diabetes and AD. Without excluding possible contributions of Aβ and tau tangle pathology to the development of type-2 diabetes, our alternative interpretation only serves to emphasize the need for in vivo studies that can further elucidate the temporal sequence of amylin- and Aβ-mediated pathological events involving type-2 diabetes and AD.
References


